The primary objective of this study is to determine in patients with non-acute Anterior Cruciate Ligament Deficiency (ACLD) whether a strategy of non-surgical management \[Rehabilitation\] (with option for later ACL reconstruction, only if required) is more clinically effective and cost effective than a strategy of surgical management \[Reconstruction\].
The ACL SNNAP study is a pragmatic multi-centre randomised controlled trial with two-arm parallel groups and 1:1 allocation ratio to compare non-surgical management (Rehabilitation) and surgical management (Reconstruction) options for patients with a symptomatic non-acute ACL deficient knee. The objective is to determine, in patients with non-acute Anterior Cruciate Ligament Deficiency (ACLD), whether non-surgical treatment (with the option for later ACL reconstruction if required) is more effective than surgical ACL reconstruction (as measured by the Knee Injury and Osteoarthritis Outcome Score \[KOOS4\] at 18 months from randomisation). Target sample size is 320 patients recruited from approx. 30 NHS orthopaedic units. An internal pilot will be conducted with clear progression criteria regarding recruitment. Both interventions are routine NHS treatments. Intervention content is based on a minimal set of pre-established criteria in order to ensure the integrity of the comparison while allowing for varying in practice in delivering the interventions between both surgeons and physiotherapists. This largely pragmatic approach will allow clinical management to reflect current practice and resource use within the NHS thus aiding generalisation. Other than the allocated intervention, both groups will be followed-up in the same way to exclude bias. Follow up for study purposes will be by patient self-reported questionnaire completed using an electronic data capture collection system (a postal option will also be available). The questionnaire will include the outcomes indicated in section 4 and will be completed by participants at baseline, 6, 12 and 18 months. Non-response will be minimised through use of multiple reminders such as web based, phone and text. Neither participants nor health care practitioners (surgeons and physiotherapists) can be blinded to receipt of the intervention.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
320
Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
Knee Injury and Osteoarthritis Outcome Score (KOOS4)
The score is derived from 4 of 5 subscales; pain, symptoms, difficulty in sports and recreational activities, knee related quality of life.
Time frame: 18 months post randomisation
Knee Injury and Osteoarthritis Outcome Score (KOOS)
All 5 subscales of the KOOS will be included (the fifth scale being activities of daily living). Anterior Cruciate Ligament Quality of Life Score (ACL-QOL)
Time frame: At baseline and at 6, 12 and 18 months post randomisation
Modified Tegner scale
Activity level will be assessed using the Modified Tegner scale, graded from 1 (low activity levels) to 10 (professional level).
Time frame: At baseline and at 6, 12 and 18 months post randomisation
Intervention related complications
Any complications associated with undergoing ACL deficiency treatment will be recorded. This includes; for surgery group; re-admission, delayed hospital discharge, infection, unexpected poor range of movement (stiffness), excess bleeding, continued swelling, episodes of giving way, continued feeling of instability. For non-surgical group; continued swelling, episodes of giving way.
Time frame: At 6, 12 and 18 months post randomisation
EuroQol EQ-5D-5L
Generic quality of life (self-reported outcome measure covering 5 health domains and used to facilitate the calculation of Quality Adjusted Life Years in health economic evaluations).
Time frame: At baseline and at 6, 12 and 18 months post randomisation
Resource-usage data
Detailed resource use data on initial treatments received (surgical reconstruction or rehabilitation) and on subsequent healthcare contacts including re-operations (surgery arm), subsequent surgical reconstructions (rehabilitation arm), surgery-related complications, further rehabilitation, and primary care and other secondary care contacts out to 18 months post-randomisation. In addition, data will be collected on ability to work (e.g. sickness absences/return to work number of days off work and subjective working ability).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Betsi Cadwaladr University Health Board
Bangor, United Kingdom
RECRUITINGBasildon and Thurrock University Hospitals NHS Foundation Trust
Basildon, United Kingdom
RECRUITINGNorth Bristol NHS Trust
Bristol, United Kingdom
RECRUITINGGloucestershire Hospitals NHS Foundation Trust
Cheltenham, United Kingdom
RECRUITINGCountess of Chester Hospital NHS Foundation Trust
Chester, United Kingdom
RECRUITINGUniversity Hospitals Coventry and Warwickshire NHS Trust
Coventry, United Kingdom
RECRUITINGFrimley Health NHS Foundation Trust
Frimley, United Kingdom
RECRUITINGRoyal Surrey County Hospitals NHS Foundation Trust
Guildford, United Kingdom
RECRUITINGHull and East Yorkshire Hospitals NHS Trust
Hull, United Kingdom
RECRUITINGLeeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
RECRUITING...and 22 more locations
Time frame: 18 months post randomisation
Anterior Cruciate Ligament Quality of Life score (ACL-QOL)
Expectations of return to activity and confidence in relation to the knee.
Time frame: At baseline and at 6, 12 and 18 months post randomisation
Patient satisfaction
Simple Likert scale
Time frame: At baseline and at 6, 12 and 18 months post randomisation